amphetamine has been researched along with Cardiovascular Diseases in 3 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prescription amphetamines are utilized for treatment of depression in older adults, yet cardiovascular risks in this population are not well described." | 8.12 | Cardiovascular Outcomes Among Older Individuals With Depression Prescribed Amphetamines: A Retrospective Cohort Study. ( Bone, C; Clegg, TJ; Latronica, JR; Silvis, ML; Tuan, WJ, 2022) |
| "Prescription amphetamines are utilized for treatment of depression in older adults, yet cardiovascular risks in this population are not well described." | 4.12 | Cardiovascular Outcomes Among Older Individuals With Depression Prescribed Amphetamines: A Retrospective Cohort Study. ( Bone, C; Clegg, TJ; Latronica, JR; Silvis, ML; Tuan, WJ, 2022) |
| "Methamphetamine abuse is a global epidemic associated with a wide-ranging array of adverse effects on the cardiovascular system including dilated cardiomyopathy, malignant and benign arrhythmias, coronary vasospasm, and atherosclerotic coronary artery disease." | 2.82 | Cardiovascular disease associated with methamphetamine use: a review. ( Afari, ME; Sawyer, DB; Song, SJ; Tobolski, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Latronica, JR | 1 |
| Tuan, WJ | 1 |
| Clegg, TJ | 1 |
| Silvis, ML | 1 |
| Bone, C | 1 |
| Tobolski, J | 1 |
| Sawyer, DB | 1 |
| Song, SJ | 1 |
| Afari, ME | 1 |
| Langendijk, PN | 1 |
| Wilde, AA | 1 |
1 review available for amphetamine and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular disease associated with methamphetamine use: a review.
Topics: Amphetamine; Calcium; Cardiovascular Diseases; Catecholamines; Humans; Methamphetamine; Reactive Oxy | 2022 |
2 other studies available for amphetamine and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular Outcomes Among Older Individuals With Depression Prescribed Amphetamines: A Retrospective Cohort Study.
Topics: Aged; Amphetamine; Amphetamines; Cardiovascular Diseases; Central Nervous System Stimulants; Cohort | 2022 |
[Medication for ADHD and the risk of cardiovascular mortality].
Topics: Amphetamine; Arrhythmias, Cardiac; Attention Deficit Disorder with Hyperactivity; Cardiovascular Dis | 2006 |